
Opinion|Videos|December 18, 2024
Other Lipid Biomarkers
Key Takeaways
- Pediatric lipid screening is vital for early dyslipidemia detection, reducing future cardiovascular disease risk.
- Guidelines suggest universal screening at ages 9-11 and 17-21, with selective screening for at-risk children.
Panelists discuss how comprehensive lipid assessment should include VLDL, HDL, triglycerides, and relevant ratios as they provide valuable insights into cardiovascular risk beyond LDL-C measurements alone.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- What considerations do you give to other lipid biomarkers, such as very low-density lipoprotein (VLDL), high-density lipoprotein (HDL), and triglycerides? Should clinicians be looking at ratios, such as TC/HCL or LDL/HDL?
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
OMA 2026 Recap: Pediatrics, Retention, and Lifestyle Changes in Obesity
2
A Real-World Case: Initiating Ritlecitinib After Years of Untreated Disease
3
Choosing Among Approved JAK Inhibitors: Baricitinib, Ritlecitinib, and Deuruxolitinib
4
CX11 Shows Weight Loss in Phase 2 Obesity Trial, Corxel Reports
5





































































